Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 30, 2023
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
[ Thu, Nov 30th 2023
] - WOPRAI
Jay Olson Maintained (BIVI) at Buy with Decreased Target to $50 on, Nov 30th, 2023
Jay Olson of Oppenheimer, Maintained "BioVie Inc." (BIVI) at Buy with Decreased Target from $120 to $50 on, Nov 30th, 2023.
Jay has made no other calls on BIVI in the last 4 months.
There is 1 other peer that has a rating on BIVI. Out of the 1 peers that are also analyzing BIVI, 0 agree with Jay's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jay
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Tuesday, August 22nd, 2023
